Spinal Simplicity’s IntraLink injectable device for disc degradation earned the FDA’s breakthrough device designation, according to an Aug. 14 news release.
IntraLink uses self-polymerizing plant-derived compounds that attach to collagen fibrils in the disc. It mechanically supports the disc to inhibit excess motion and stabilize the spinal joint.
With breakthrough designation IntraLink will get priority FDA review and streamlined, collaborative communication through the premarket review process.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.